Dr. Dean is a leader in the field of oligonucleotide therapeutics, with an emphasis on pharmacology and serves as an Independent Consultant in the Biotech industry. He founded Excaliard Pharmaceuticals in 2006 – an RNAi company focused on developing antisense-based drugs to treat skin scarring, and which was later acquired by Pfizer in 2011. Prior to this, Dr. Dean was vice president of Functional Genomics and Oncology at Isis Pharmaceuticals, where he also served as managing director of Isis Singapore. He originally joined Isis Pharmaceuticals in 1991 and served in various roles in the molecular pharmacology department until 2000, at which time he became executive director and vice president, Functional Genomics for Isis Pharmaceuticals. He is a member of the editorial board of Antisense & Nucleic Acid Research and Drug Discovery Today: Technologies. He served as a Member of Scientific Advisory Board at Galena Biopharma, Inc., since March 2007 and Arcturus Therapeutics since May 2013. He has also served as member of the Scientific Advisory Board of RXi Pharmaceuticals Corp. Dr. Dean has published over 120 scientific articles, and has over 50 issued patents. Dr. Dean received his Bachelor of Science degree from the University of Wales. He completed his PhD at the Welsh National School of Medicine (Cardiff) in 1984 before conducting post-doctoral research at the National Institutes of Health and the University of Hawaii.
David Ward, PhD
Dr. Ward is a prominent research scientist with significant expertise in virology, molecular genetics, cytogenetics and biotechnology. He is author on over 300 manuscripts and has been issued more than 40 patents while faculty at Yale University. Over 20 of his patents are still in use in the clinical diagnostic and therapeutic areas, including non-isotopic nuclei acid labeling techniques, single and multiparametric fluorescence in situ hybridization (FISH) in cancer diagnostics, the Abbott Urovision™ test for bladder cancer and the LabCorp 6-plex protein blood test for detection of ovarian cancer, molecular cytogenetics (M-FISH or spectral karyotyping [SKY]) and prenatal diagnosis of Down Syndrome and other disorders with chromosomal abnormalities. Dr. Ward was elected to the National Academy of Sciences of the United States in 1998.
Hari Nadiminti, MD MBA
Dr. Nadiminti is the Chairman of Dermatology at the Summit Medical Group, the largest multispecialty group in New Jersey. He has experience and expertise in clinical trials and was a research fellow at the National Institute of Health. Dr. Nadiminti is the recipient of the MDx Medical, Inc. Patients’ Choice Award and American Society of Dermatologic Surgery Young Investigators Writing Award. He has been featured in New Jersey Monthly “Top Doctors” listings. He is a member of the American College of Mohs Surgery, American Society of Dermatologic Surgery, American Academy of Dermatology, and American Medical Association. Dr. Nadiminti received his Bachelor of Science from the University of Miami, his MD at the University of Miami School of Medicine, and completed residency in dermatology at Cornell University Medical College, New York.